Trial Profile
Retrospective study of adjuvant sunitinib in high risk uveal melanoma
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 24 Oct 2018
Price :
$35
*
At a glance
- Drugs Sunitinib (Primary)
- Indications Uveal melanoma
- Focus Therapeutic Use
- 21 Jul 2015 New trial record
- 02 Jun 2015 Results (n=105) presented at the 51st Annual Meeting of the American Society of Clinical Oncology.